Last10K.com

Kezar Life Sciences, Inc. (KZR) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2019

Kezar Life Sciences, Inc.

CIK: 1645666 Ticker: KZR

Exhibit 99.1

 

Kezar Life Sciences Reports Fourth Quarter and Year End 2019 Financial Results and Provides Business Update

 

Phase 2 MARINA, MISSION and PRESIDIO trials with KZR-616 are progressing

 

Additional data from the ongoing Phase 1b portion of the MISSION study to be presented during various medical conferences throughout the course of 2020

 

KZR-261, a first-in-class protein secretion inhibitor, is currently undergoing IND-enabling activities towards filing in Q1 2021  

SAN FRANCISCO, Calif., March 12, 2020 -- Kezar Life Sciences, Inc. (Nasdaq: 

KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its fourth quarter and year end 2019 financial results and corporate highlights.

2019 marked several key milestones for Kezar, and I’m grateful for our team’s skill and hard work moving both of our programs forward.  Our selective immunoproteasome inhibitor, KZR-616, entered Phase 2 trials in five different autoimmune diseases of high unmet need, building upon encouraging data from our ongoing Phase 1b study.  We also nominated KZR-261, the first clinical candidate from our protein secretion program, and expect an IND filing in early 2021”, said John Fowler, Chief Executive Officer. “This year we look forward to sharing updates from the Phase 1b portion of our MISSION study, as well as an interim analysis from our MARINA trial in AIHA and ITP.  Finally, after our successful financing last month, we have a strong cash position that takes us beyond all of our KZR-616 Phase 2 readouts as well as data with KZR-261 in multiple tumor types.” 

Recent Clinical and Business Highlights

KZR-616 – Selective Immunoproteasome Inhibitor

MISSION Study

The Phase 1b/2 MISSION study in systemic lupus erythematosus (SLE) patients with and without nephritis is currently ongoing.  

 

Additional data from the Phase 1b portion of MISSION will be presented during various medical conferences throughout the course of 2020.

 

 

The Phase 2 portion of MISSION is a randomized, placebo-controlled, double-blind trial to evaluate the safety and efficacy of KZR-616 in patients with active proliferative lupus nephritis. The primary endpoints of this portion of the MISSION trial are safety and tolerability. Secondary and exploratory endpoints include pharmacokinetics (PK), pharmacodynamics (PD), biomarker assessments and additional measures of efficacy. This trial includes four treatment arms evaluating KZR-616 administered subcutaneously once weekly for 24 weeks at dose levels of 30 mg, 45 mg and 60 mg, compared to placebo. The trial is designed to enroll up to 64 patients.


The following information was filed by Kezar Life Sciences, Inc. (KZR) on Thursday, March 12, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Kezar Life Sciences, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Kezar Life Sciences, Inc..

Continue

Assess how Kezar Life Sciences, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Kezar Life Sciences, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statement Of Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit)
Consolidated Statement Of Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Comprehensive Loss
Consolidated Statements Of Operations
Available-For-Sale Securities
Available-For-Sale Securities (Tables)
Available-For-Sale Securities - Additional Information (Details)
Available-For-Sale Securities - Summary Of Amortized Cost And Estimated Fair Value Of Available-For-Sale Securities By Contractual Maturity (Details)
Available-For-Sale Securities - Summary Of Available-For-Sale Securities Recorded In Cash And Cash Equivalents Or Marketable Securities (Details)
Balance Sheet Components
Balance Sheet Components (Tables)
Balance Sheet Components - Accrued Liabilities (Details)
Balance Sheet Components - Additional Information (Details)
Balance Sheet Components - Property And Equipment (Details)
Commitments And Contingencies
Defined Contribution Plan
Defined Contribution Plan - Additional Information (Details)
Fair Value Measurements
Fair Value Measurements (Tables)
Fair Value Measurements - Additional Information (Detail)
Fair Value Measurements - Summary Of Financial Assets Measured At Fair Value On Recurring Basis (Details)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Details)
Income Taxes - Schedule Of Components Of Deferred Tax Assets And Liabilities (Details)
Income Taxes - Schedule Of Domestic And Foreign Components Of Net Loss (Details)
Income Taxes - Schedule Of Effective Tax Rate Of Provision For Income Taxes Differs From Federal Statutory Rate (Details)
Lease
Lease (Tables)
Lease - Additional Information (Details)
Lease - Details Of Right-Of-Use Assets And Lease Liabilities (Details)
Lease - Schedule Of Future Minimum Lease Payments Under Noncancelable Facility Operating Lease (Details)
License Agreement
License Agreement - Additional Information (Details)
Net Loss Per Share
Net Loss Per Share (Tables)
Net Loss Per Share - Anti-Dilutive Outstanding Shares Of Common Stock Equivalents Excluded From Computation Of Diluted Net Loss Per Share (Details)
Net Loss Per Share - Calculation Of Basic And Diluted Net Loss Per Share (Details)
Organization And Description Of The Business
Organization And Description Of The Business - Additional Information (Details)
Redeemable Convertible Preferred Stock
Redeemable Convertible Preferred Stock - Additional Information (Details)
Selected Quarterly Financial Information (Unaudited)
Selected Quarterly Financial Information (Unaudited) (Tables)
Selected Quarterly Financial Information (Unaudited) - Schedule Of Selected Quarterly Financial Information (Unaudited) (Details)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Details)
Stock-Based Compensation - Fair Value Of Employee Stock Options Granted And Espp Rights To Purchase Common Stock Calculated Using Black Scholes Option Pricing Model With Weighted Average Assumptions (Details)
Stock-Based Compensation - Stock-Based Compensation Expense Recognized (Details)
Stock-Based Compensation - Summarizes Of Activity Of Nonvested Restricted Stock (Details)
Stock-Based Compensation - Summary Of Activity Under Stock Option Plans And Related Information (Details)
Subsequent Events
Subsequent Events - Additional Information (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Additional Information (Details)
Summary Of Significant Accounting Policies - Impact Of Accounting Pronouncements Adoption On Balance Sheet (Details)
Summary Of Significant Accounting Policies - Schedule Of Reconciliation Of Cash, Cash Equivalents And Restricted Cash (Detail)
Ticker: KZR
CIK: 1645666
Form Type: 10-K Annual Report
Accession Number: 0001564590-20-010498
Submitted to the SEC: Thu Mar 12 2020 4:34:49 PM EST
Accepted by the SEC: Thu Mar 12 2020
Period: Tuesday, December 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/kzr/0001564590-20-010498.htm